Fluticasone propionate powder administered by means of Diskus or Diskhaler significantly improved FEV1 ( mean increase from baseline of 0.22 to 0.24 L ; p < or = 0.023 ) , clinic morning peak expiratory flow ( mean increase from baseline of 48 to 55 L/min ; p < or = 0.006 ) , patient-measured morning ( p < or = 0.001 ) and evening ( p < or = 0.003 ) peak expiratory flow , and asthma symptom scores ( in all but the 50 microg Diskus group ; p < or = 0.036 ) , as well as reduced albuterol use ( p < or = 0.002 ) and nighttime awakenings ( p < or = 0.019 ) at endpoint .
